Check out the following recent activity in the biopharma funding space. This mix of private investments and public grants fuels important research and development across the industry. Take a closer look at some of the notable updates for this week:
– Private Funding Rounds –
Siolta Therapeutics
🏦 Raised $12M in Series C financing for clinical development co-led by SymBiosis and Khosla Ventures to advance the development of STMC-103H for atopic disorders.
Tubulis
🏦 Closed €128M Series B2 funding round co-led by EQT Life Sciences and Nextech Invest to progress the development of their ADC drug pipelines.
Asgard Therapeutics
🏦 Secured $32M Series A financing from J&J, Novo, and Boehringer to advance its lead program candidate, AT-108.
Relation Therapeutics
🏦 Raised $35M in seed funding led by DCVC & NVentures totaling $60M to advance its therapeutic pipeline for Osteoporosis.
Alithea Genomics
🏦 Raised $3.2M from seed financing extension led by Novalis Biotech to further commercialize its unique RNA seq. products and advance new technology developments.
Mission Therapeutics
🏦 Raised £25.2M led by several investors to progress clinical candidates (MTX325 and MTX652) in the area of mitophagy.
– Grants –
Gilgamesh Pharmaceuticals
🏦 Awarded $14M NIDA grant to advance GM-3009 treating opioid use disorder.
Orgenesis
🏦 Awarded €1.5M grant from the Walloon Government for the EXOFASTTRACK project dedicated to the development of multiple therapeutic exosomes.
ABIONYX Pharma
🏦 Received €1M Non-dilutive Innovation Grant from Bpifrance to support the development of CER-001 treating severe indications in ophthalmology.
Theromics Inc.
🏦 Granted $1M STTRE Ph2 grant from the National Science Foundation for the innovative ablation therapy technology (HeatSYNC™).
– Equity Financing –
Cybin
🏦 Oversubscribed private placement of $150M led by Deep Track Capital.
Regulus Therapeutics
🏦 Secured $100M private placement.
Lexeo Therapeutics
🏦 Closed oversubscribed $95M equity financing.
Unicycive Therapeutics
🏦 $50M private placement led by Octagon Capital & Great Point Partners.
Eupraxia Pharmaceuticals
🏦 Closed overnight marketed offering C$33.9M.
Sellas Life Sciences
🏦 $20M registered direct offering and concurrent private placement.
Renalytix
🏦 Completed upsized $12M equity placing.
Cognition Therapeutics
🏦 Closed $11.5M public offering.
Delcath Systems
🏦 $7M private placement.
ASLAN Pharmaceuticals
🏦 Entered into a $5M registered direct offering.
Scorpius Holdings
🏦 Closed $1.5M public offering.
Devonian
🏦 Closed $223.8K private placement offering.
---
Interested in these updates? Get the full update each week → https://www.biopharmiq.com/#subscribe
Article History:
RF, DV (03/18/24)
Comments